^
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
04/12/2019
Primary completion :
02/28/2023
Completion :
02/28/2023
PD-L1 • CD4
|
Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase N/A
Hoffmann-La Roche
Recruiting
Last update posted :
10/15/2021
Initiation :
02/07/2019
Primary completion :
12/19/2026
Completion :
12/19/2026
EGFR • PD-L1 • ALK
|
PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation
|
Tecentriq (atezolizumab)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
04/19/2019
Primary completion :
06/01/2025
Completion :
06/01/2025
PD-L1 • CD4
|
cisplatin • Tecentriq (atezolizumab) • gemcitabine • fluorouracil topical
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
06/07/2018
Primary completion :
08/30/2023
Completion :
12/30/2023
PD-L1 • PD-1 • EPCAM
|
Imfinzi (durvalumab) • Vicineum (oportuzumab monatox)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/15/2021
Initiation :
05/17/2019
Primary completion :
06/30/2022
Completion :
06/30/2022
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
10/15/2021
Initiation :
05/20/2021
Primary completion :
05/01/2022
Completion :
05/01/2023
PD-L1
|
Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin)
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
05/09/2016
Primary completion :
07/01/2023
Completion :
12/31/2027
BRCA
|
Lynparza (olaparib) • irinotecan
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/14/2021
Initiation :
09/28/2018
Primary completion :
12/31/2021
Completion :
12/31/2021
PD-L1 • CD4
|
PD-L1 expression
|
Tecentriq (atezolizumab) • glycosylated recombinant human interleukin-7 (CYT107)
Phase 2
IO Biotech
Not yet recruiting
Last update posted :
10/14/2021
Initiation :
10/31/2021
Primary completion :
12/31/2022
Completion :
11/30/2024
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • IO103
Phase 3
Pfizer
Active, not recruiting
Last update posted :
10/14/2021
Initiation :
04/25/2016
Primary completion :
10/21/2019
Completion :
06/03/2022
PD-L1 • CD8
|
PD-L1 expression
|
Bavencio (avelumab)
Phase 2
Astellas Pharma Global Development, Inc.
Active, not recruiting
Last update posted :
10/13/2021
Initiation :
10/08/2017
Primary completion :
10/27/2020
Completion :
05/31/2025
PD-L1 • PD-1
|
cisplatin • Padcev (enfortumab vedotin)
Phase 1a/1b
Genentech, Inc.
Recruiting
Last update posted :
10/12/2021
Initiation :
12/21/2017
Primary completion :
02/01/2024
Completion :
02/01/2024
HER-2 • ER • PGR
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
Phase 1/2
Fudan University
Recruiting
Last update posted :
10/12/2021
Initiation :
06/09/2021
Primary completion :
09/01/2022
Completion :
06/01/2023
PD-1
|
PD-L1 expression • PD-1 expression
|
AiRuiKa (camrelizumab)
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/11/2021
Initiation :
09/21/2017
Primary completion :
06/01/2025
Completion :
06/01/2025
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/11/2021
Initiation :
07/24/2019
Primary completion :
06/26/2026
Completion :
05/12/2027
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • Padcev (enfortumab vedotin)
Phase 1b
NeoTX Therapeutics Ltd.
Recruiting
Last update posted :
10/11/2021
Initiation :
10/10/2019
Primary completion :
04/01/2022
Completion :
07/28/2022
HER-2 • ER • TPBG
|
HER-2 negative • TPBG positive
|
Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
Phase 1
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/08/2021
Initiation :
12/03/2021
Primary completion :
09/01/2023
Completion :
09/01/2023
FGFR2
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/08/2021
Initiation :
08/20/2020
Primary completion :
01/31/2022
Completion :
01/31/2022
PD-L1 • TP53 • PTEN • RB1
|
Yervoy (ipilimumab) • valemetostat (DS-3201)
Phase 1b/2
Pfizer
Active, not recruiting
Last update posted :
10/08/2021
Initiation :
12/21/2017
Primary completion :
06/30/2022
Completion :
06/30/2022
PD-L1 • ALK • TMB • ROS1
|
PD-L1 expression • ALK translocation
|
cisplatin • carboplatin • gemcitabine • Bavencio (avelumab) • pemetrexed
Phase N/A
Janssen Research & Development, LLC
Recruiting
Last update posted :
10/08/2021
Initiation :
08/01/2019
Primary completion :
04/04/2023
Completion :
04/04/2023
FGFR
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
10/08/2021
Initiation :
09/27/2004
Primary completion :
09/11/2006
Completion :
09/01/2007
CD8 • CTAG1B • CD4 • CTAG2
|
CTAG1B expression
Phase 2
Janssen Research & Development, LLC
Recruiting
Last update posted :
10/08/2021
Initiation :
04/22/2015
Primary completion :
06/30/2022
Completion :
12/31/2023
FGFR
|
Balversa (erdafitinib) • metformin • midazolam hydrochloride
Phase 2
Janssen Research & Development, LLC
Recruiting
Last update posted :
10/08/2021
Initiation :
02/28/2020
Primary completion :
10/26/2022
Completion :
12/31/2026
FGFR
|
FGFR mutation • FGFR fusion
|
gemcitabine • Balversa (erdafitinib) • mitomycin
Phase 3
Pfizer
Recruiting
Last update posted :
10/07/2021
Initiation :
12/30/2019
Primary completion :
06/03/2024
Completion :
12/02/2026
PD-L1
|
PD-L1 expression • PD-L1 overexpression
|
sasanlimab (PF-06801591)
Phase 3
National Cancer Institute (NCI)
Recruiting
Last update posted :
10/07/2021
Initiation :
05/06/2021
Primary completion :
09/30/2027
Completion :
09/30/2027
CD4
|
cisplatin • gemcitabine • Imfinzi (durvalumab) • doxorubicin hydrochloride • methotrexate • methotrexate IV • Fulphila (pegfilgrastim-jmdb) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Pegcyte (pegfilgrastim biosimilar) • Udenyca (pegfilgrastim biosimilar) • Ziextenzo (pegfilgrastim biosimilar) • liposomal gemcitabine (FF-10832) • vinblastine
Phase 2a
Genentech, Inc.
Active, not recruiting
Last update posted :
10/07/2021
Initiation :
04/14/2014
Primary completion :
12/30/2022
Completion :
12/30/2022
EGFR • HER-2 • BRAF • ALK • TMB • PTCH1 • SMO
|
EGFR mutation • HER-2 amplification • HER-2 overexpression • BRAF mutation • BRAF V600 • ALK rearrangement • ALK mutation • SMO mutation
|
Herceptin (trastuzumab) • erlotinib • Zelboraf (vemurafenib) • Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Erivedge (vismodegib)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
10/06/2021
Initiation :
11/12/2021
Primary completion :
04/30/2023
Completion :
04/30/2023
IL2
|
Tecentriq (atezolizumab)
Phase 1/2
Hoffmann-La Roche
Recruiting
Last update posted :
10/06/2021
Initiation :
06/01/2019
Primary completion :
11/01/2024
Completion :
11/09/2024
PD-L1
|
cisplatin • Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin) • magrolimab (Hu5F9-G4) • tiragolumab (MTIG7192A) • Actemra IV (tocilizumab) • RO7121661
Phase 1/2
Istari Oncology, Inc.
Recruiting
Last update posted :
10/05/2021
Initiation :
08/01/2021
Primary completion :
05/01/2025
Completion :
05/01/2025
CD4
|
PD-L1 expression • CDKN2A negative
|
PVS-RIPO
Phase 1b/2
Pharmacyclics LLC.
Completed
Last update posted :
10/05/2021
Initiation :
11/01/2015
Primary completion :
08/20/2021
Completion :
08/20/2021
EGFR • KRAS
|
EGFR expression
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ibrutinib • paclitaxel • everolimus • docetaxel
Phase 1
Seagen Inc.
Recruiting
Last update posted :
10/05/2021
Initiation :
06/08/2020
Primary completion :
11/30/2023
Completion :
11/30/2023
HER-2
|
HER-2 negative
|
SGN-B6A
Phase 1
Adaptimmune
Active, not recruiting
Last update posted :
10/05/2021
Initiation :
07/05/2017
Primary completion :
09/01/2032
Completion :
09/01/2035
HLA-A • MAGEA4
|
HLA-A2 positive
|
afamitresgene autoleucel (ADP-A2M4)
Phase 1b
ADC Therapeutics S.A.
Recruiting
Last update posted :
10/04/2021
Initiation :
11/09/2018
Primary completion :
11/15/2022
Completion :
11/15/2023
MSI
|
Keytruda (pembrolizumab) • camidanlumab tesirine (ADCT-301)
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/04/2021
Initiation :
09/14/2015
Primary completion :
09/01/2022
Completion :
09/01/2022
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
10/04/2021
Initiation :
07/09/2015
Primary completion :
09/30/2022
Completion :
09/30/2022
PD-L1 • MET
|
PD-L1 expression • MET expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
Phase 1/2
Taiho Oncology, Inc.
Completed
Last update posted :
10/04/2021
Initiation :
07/01/2014
Primary completion :
09/30/2020
Completion :
05/29/2021
FGFR2
|
FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR fusion • FGFR2 rearrangement
|
futibatinib (TAS 120)
Phase 3
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
10/01/2021
Initiation :
07/24/2019
Primary completion :
06/26/2026
Completion :
05/12/2027
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • Rituxan (rituximab) • lenvatinib • bendamustine • Padcev (enfortumab vedotin)
Phase 2
Nektar Therapeutics
Active, not recruiting
Last update posted :
10/01/2021
Initiation :
04/29/2019
Primary completion :
04/01/2022
Completion :
10/01/2022
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • bempegaldesleukin (NKTR-214)
Phase 3
Astellas Pharma Global Development, Inc.
Recruiting
Last update posted :
09/30/2021
Initiation :
03/30/2020
Primary completion :
11/30/2023
Completion :
11/30/2023
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Padcev (enfortumab vedotin)
Phase 3
Bristol-Myers Squibb
Recruiting
Last update posted :
09/30/2021
Initiation :
03/24/2017
Primary completion :
10/16/2023
Completion :
08/29/2024
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • carboplatin • Yervoy (ipilimumab) • gemcitabine
Phase 2
Novartis Pharmaceuticals
Recruiting
Last update posted :
09/30/2021
Initiation :
08/28/2017
Primary completion :
03/31/2022
Completion :
06/17/2022
EGFR • BRAF
|
BRAF V600E • EGFR mutation • EGFR T790M
|
spartalizumab (PDR001) • taminadenant (NIR178)
Phase 1
Pfizer
Not yet recruiting
Last update posted :
09/29/2021
Initiation :
10/01/2021
Primary completion :
07/07/2024
Completion :
07/07/2024
IL2
|
sasanlimab (PF-06801591) • PF-07263689
Phase 1
Astellas Pharma Global Development, Inc.
Active, not recruiting
Last update posted :
09/29/2021
Initiation :
06/04/2014
Primary completion :
12/31/2021
Completion :
12/31/2021
NECTIN4
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/28/2021
Initiation :
07/26/2005
Primary completion :
02/05/2014
HER-2
|
Herceptin (trastuzumab) • paclitaxel • Herzuma (trastuzumab biosimilar) • Ontruzant (trastuzumab biosimilar) • Ogivri (trastuzumab biosimilar) • EG12014 (trastuzumab biosimilar) • EG-12 • GB221 (trastuzumab biosimilar) • SIBP-01 (trastuzumab biosimilar)
Phase 1/2
Ascentage Pharma Group Inc.
Recruiting
Last update posted :
09/28/2021
Initiation :
08/29/2018
Primary completion :
10/30/2022
Completion :
01/31/2023
PD-L1 • ATM
|
ATM mutation
|
Keytruda (pembrolizumab) • alrizomadlin (APG-115)
Phase 1/2
Bicycle Tx Limited
Recruiting
Last update posted :
09/28/2021
Initiation :
07/17/2020
Primary completion :
06/01/2023
Completion :
06/01/2023
EGFR • ALK • NECTIN4
|
NECTIN4 expression
|
Opdivo (nivolumab) • BT8009
Phase 
Guardant Health, Inc.
Recruiting
Last update posted :
09/28/2021
Initiation :
09/07/2021
Primary completion :
10/01/2027
Completion :
10/01/2027
HER-2
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
09/28/2021
Initiation :
11/02/2015
Primary completion :
01/27/2020
Completion :
03/29/2024
PD-L1
|
PD-L1 underexpression • PD-L1 negative • PD-L1-H
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 2
Vasgene Therapeutics, Inc
Recruiting
Last update posted :
09/28/2021
Initiation :
08/14/2020
Primary completion :
12/31/2025
Completion :
12/31/2025
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • sEphB4-HSA
Phase 2
University of Chicago
Recruiting
Last update posted :
09/28/2021
Initiation :
10/30/2013
Primary completion :
06/12/2022
Completion :
06/12/2023
EGFR • HER-2
|
HER-2 expression • EGFR expression
|
Gilotrif (afatinib)
Phase 1
MacroGenics
Completed
Last update posted :
09/28/2021
Initiation :
07/01/2015
Primary completion :
08/18/2021
Completion :
08/18/2021
CD276
|
CD276 expression
|
Keytruda (pembrolizumab) • cisplatin • retifanlimab (INCMGA0012) • enoblituzumab (MGA271)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
09/28/2021
Initiation :
09/23/2021
Primary completion :
06/30/2023
Completion :
06/30/2023
BRAF
|
EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR T790M negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab) • Actemra SC (tocilizumab SC)
Phase 1/2
Cancer Research UK
Not yet recruiting
Last update posted :
09/27/2021
Initiation :
09/01/2021
Primary completion :
09/01/2026
Completion :
09/01/2026
NRG1 • ERBB3
|
ERBB3 expression • NRG1 fusion • ERBB3 overexpression
|
HMBD-001
Phase 
xCures
Recruiting
Last update posted :
09/22/2021
Initiation :
09/01/2021
Primary completion :
08/01/2022
Completion :
08/01/2022
FGFR
|
Balversa (erdafitinib)
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
09/24/2018
Primary completion :
09/30/2021
Completion :
09/30/2021
HAVCR2
|
INCAGN2390
Phase 2
Incyte Corporation
Active, not recruiting
Last update posted :
09/22/2021
Initiation :
01/09/2019
Primary completion :
10/30/2020
Completion :
07/06/2022
PD-L1 • ALK
|
PD-L1 expression • PD-L1 overexpression
|
retifanlimab (INCMGA0012)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
09/22/2021
Initiation :
05/01/2019
Primary completion :
07/01/2023
Completion :
12/01/2024
HER-2 • ER • PGR
|
HER-2 negative
|
Yervoy (ipilimumab) • izuralimab (XmAb23104)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/21/2021
Initiation :
11/04/2020
Primary completion :
11/02/2025
Completion :
11/02/2025
CD4
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CMAB 819 (nivolumab biosimilar)
Phase 1
Pfizer
Recruiting
Last update posted :
09/20/2021
Initiation :
11/13/2019
Primary completion :
01/06/2024
Completion :
01/06/2024
PD-1
|
sasanlimab (PF-06801591) • PF-06940434
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
09/20/2021
Initiation :
05/06/2019
Primary completion :
10/31/2023
Completion :
10/31/2023
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • lenvatinib
Phase 3
Merck Sharp & Dohme Corp.
Completed
Last update posted :
09/20/2021
Initiation :
10/22/2014
Primary completion :
09/07/2016
Completion :
10/01/2020
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin • paclitaxel • docetaxel • Javlor (vinflunine)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
09/17/2021
Initiation :
08/19/2016
Primary completion :
08/31/2022
Completion :
08/31/2022
ERCC2 • CDKN1A
|
cisplatin • gemcitabine • berzosertib (M6620) • liposomal gemcitabine (FF-10832)
Phase N/A
AstraZeneca
Recruiting
Last update posted :
09/16/2021
Initiation :
05/18/2020
Primary completion :
05/29/2023
Completion :
05/29/2023
PD-L1
|
PD-L1 expression • PD-L1 overexpression
Phase 2
RemeGen Co., Ltd.
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
01/07/2019
Primary completion :
03/04/2021
Completion :
12/31/2021
HER-2
|
HER-2 overexpression
|
cisplatin • Aidixi (disitamab vedotin)
Phase 1
South Metropolitan Health Service
Recruiting
Last update posted :
09/16/2021
Initiation :
05/14/2021
Primary completion :
03/31/2022
Completion :
12/31/2022
CA9
|
Rencarex (girentuximab)
Phase 2
RemeGen Co., Ltd.
Active, not recruiting
Last update posted :
09/16/2021
Initiation :
08/19/2019
Primary completion :
06/28/2021
Completion :
09/30/2022
HER-2
|
HER-2 negative
|
cisplatin • Aidixi (disitamab vedotin)
Phase 1
Seagen Inc.
Recruiting
Last update posted :
09/15/2021
Initiation :
05/29/2020
Primary completion :
12/31/2022
Completion :
03/31/2023
TIGIT
|
sasanlimab (PF-06801591) • SGN-TGT
Phase 1
Carisma Therapeutics Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
02/02/2021
Primary completion :
02/01/2022
Completion :
02/01/2023
HER-2
|
HER-2 positive • HER-2 overexpression
|
CT-0508
Phase 1b/2
Sumitomo Dainippon Pharma Oncology, Inc
Recruiting
Last update posted :
09/10/2021
Initiation :
12/14/2017
Primary completion :
08/01/2023
Completion :
02/01/2024
MSI • HLA-A
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
Phase 1
The Methodist Hospital Research Institute
Recruiting
Last update posted :
09/09/2021
Initiation :
08/03/2018
Primary completion :
10/31/2021
Completion :
01/28/2022
BRAF • PD-L1 • TMB • MSI
|
PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/08/2021
Initiation :
02/01/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
HER-2 • ER • PGR • ATM
|
HER-2 negative • ATM mutation • ATM expression
|
cisplatin • gemcitabine • elimusertib (BAY1895344) • liposomal gemcitabine (FF-10832)
Phase N/A
University Hospital, Tours
Recruiting
Last update posted :
09/06/2021
Initiation :
09/03/2021
Primary completion :
09/01/2022
Completion :
09/01/2022
PD-L1 • CD4
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/06/2021
Initiation :
08/03/2018
Primary completion :
08/21/2023
Completion :
08/21/2023
ABL1 • TMB • BRCA1 • BRCA2 • MSI • NPM1 • STK11 • POLE • CCND1 • BAP1 • MLH1 • MSH6 • MSH2 • ATRX • POLD1 • SMARCB1 • BRIP1 • CHEK2 • RAD51 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCG • IKBKE • FANCC
|
FANCG mutation
|
Lynparza (olaparib)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
07/13/2020
Primary completion :
01/01/2022
Completion :
04/01/2022
CD4
|
PD-L1 expression
|
bintrafusp alfa (M7824) • M-9241
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/03/2021
Initiation :
10/26/2020
Primary completion :
05/01/2024
Completion :
12/01/2024
CD4
|
PD-L1 expression
|
cisplatin • bintrafusp alfa (M7824)
Phase N/A
xCures
Available
Last update posted :
09/02/2021
BRAF • NRAS • HRAS
|
BRAF mutation • ER mutation • HRAS mutation
|
ulixertinib (BVD-523)
Phase 1b
The Netherlands Cancer Institute
Recruiting
Last update posted :
09/01/2021
Initiation :
08/23/2021
Primary completion :
04/30/2023
Completion :
04/30/2023
PD-L1
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • domatinostat (4SC-202)
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
02/28/2020
Primary completion :
12/01/2021
Completion :
12/01/2022
TROP2
|
TROP2 expression
|
SKB264
Phase 1
Keythera Pharmaceuticals (Australia) Pty Ltd
Recruiting
Last update posted :
09/01/2021
Initiation :
03/09/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
PD-L1 • CD8 • IFNG • CXCL10 • TNFA
|
PD-L1 expression
|
Tecentriq (atezolizumab) • KF-0210
Phase 1/2
Klus Pharma Inc.
Recruiting
Last update posted :
09/01/2021
Initiation :
07/16/2018
Primary completion :
04/01/2022
Completion :
12/01/2022
HER-2
|
HER-2 positive • HER-2 expression • HER-2 underexpression
|
A166
Phase 1/2
Fred Hutchinson Cancer Research Center
Recruiting
Last update posted :
08/31/2021
Initiation :
07/19/2021
Primary completion :
12/01/2024
Completion :
12/01/2024
HER-2 • ALK • ROS1 • HLA-A • MAGEA1
|
EGFR mutation • HER-2 expression
|
Tecentriq (atezolizumab) • fludarabine IV • cyclophosphamide intravenous
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
08/31/2021
Initiation :
02/20/2019
Primary completion :
10/31/2021
Completion :
07/31/2022
ALB
|
Imfinzi (durvalumab) • oleclumab (MEDI9447)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
08/30/2021
Initiation :
07/10/2018
Primary completion :
10/01/2021
Completion :
10/01/2021
PD-L1
|
Keytruda (pembrolizumab) • Clostridium novyi-NT • doxycycline • doxycycline delayed-release
Phase 1
Mayo Clinic
Recruiting
Last update posted :
08/30/2021
Initiation :
02/13/2020
Primary completion :
07/31/2022
Completion :
07/31/2022
EGFR • BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • Odomzo (sonidegib)
Phase 1
Institut Cancerologie de l'Ouest
Not yet recruiting
Last update posted :
08/30/2021
Initiation :
09/01/2021
Primary completion :
10/01/2022
Completion :
10/01/2022
CA9
|
CA9 expression
|
Rencarex (girentuximab)
Phase 1b
Rahul Aggarwal
Recruiting
Last update posted :
08/30/2021
Initiation :
08/20/2018
Primary completion :
05/31/2023
Completion :
05/31/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • abexinostat (CG-781)
Phase N/A
Rutgers, The State University of New Jersey
Recruiting
Last update posted :
08/30/2021
Initiation :
09/01/2017
Primary completion :
08/31/2021
Completion :
08/31/2021
NFKB1
Phase 1
Cellex Patient Treatment GmbH
Recruiting
Last update posted :
08/25/2021
Initiation :
11/23/2020
Primary completion :
11/01/2022
Completion :
05/01/2023
FOLH1
|
FOLH1 expression
|
fludarabine IV • cyclophosphamide intravenous
Phase 2b
ImmunityBio, Inc.
Active, not recruiting
Last update posted :
08/25/2021
Initiation :
12/11/2018
Primary completion :
05/01/2023
Completion :
12/01/2023
BRAF • PD-L1 • ALK • MSI
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Anktiva (inbakicept) • PD-L1.t-haNK
Phase 1/2
Telix International Pty Ltd
Recruiting
Last update posted :
08/24/2021
Initiation :
08/03/2021
Primary completion :
02/28/2022
Completion :
05/31/2022
CA9
|
Rencarex (girentuximab)
Phase 2
AstraZeneca
Active, not recruiting
Last update posted :
08/24/2021
Initiation :
03/16/2018
Primary completion :
10/15/2020
Completion :
09/04/2023
HRD
|
Lynparza (olaparib) • Imfinzi (durvalumab)
Phase 2
The Affiliated Nanjing Drum Tower Hospital of N...
Not yet recruiting
Last update posted :
08/23/2021
Initiation :
10/01/2021
Primary completion :
09/01/2024
Completion :
10/01/2024
HER-2
|
HER-2 overexpression
|
Aidixi (disitamab vedotin)
Phase 1
Cancer Research UK
Recruiting
Last update posted :
08/20/2021
Initiation :
06/21/2017
Primary completion :
01/31/2022
Completion :
01/31/2022
TP53
|
TP53 mutation
|
LY3143921
Phase 2
Erasmus Medical Center
Active, not recruiting
Last update posted :
08/20/2021
Initiation :
08/21/2017
Primary completion :
08/19/2022
Completion :
08/19/2023
TMB
|
Keytruda (pembrolizumab)
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
08/18/2021
Initiation :
05/29/2019
Primary completion :
06/01/2024
Completion :
11/01/2025
HER-2 • PD-L1 • ER • PGR
|
HER-2 negative
|
Keytruda (pembrolizumab) • pavunalimab (XmAb22841)
Phase 1
University of California, Davis
Active, not recruiting
Last update posted :
08/18/2021
Initiation :
09/01/2015
Primary completion :
08/07/2019
Completion :
12/01/2021
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • gemcitabine • docetaxel
Phase 2
European Association of Urology Research Founda...
Recruiting
Last update posted :
08/16/2021
Initiation :
07/13/2020
Primary completion :
04/30/2024
Completion :
10/30/2024
FGFR
|
FGFR mutation
|
cisplatin • Pemazyre (pemigatinib)
Phase 2
SOLTI Breast Cancer Research Group
Recruiting
Last update posted :
08/16/2021
Initiation :
04/12/2021
Primary completion :
12/31/2023
Completion :
12/11/2024
PD-1
|
PD-1 expression
|
spartalizumab (PDR001)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
08/16/2021
Initiation :
02/07/2017
Primary completion :
03/01/2022
Completion :
03/01/2022
CD4
|
Tecentriq (atezolizumab)
Phase 2
Institut du Cancer de Montpellier - Val d'Aurelle
Recruiting
Last update posted :
08/16/2021
Initiation :
09/01/2011
Primary completion :
09/01/2022
Completion :
09/01/2025
CD8
|
cisplatin • gemcitabine
Phase 1
Craig L Slingluff, Jr
Recruiting
Last update posted :
08/13/2021
Initiation :
11/21/2019
Primary completion :
11/30/2022
Completion :
05/30/2023
PD-L1
|
Zyclara (imiquimod)
Phase 2
The Affiliated Nanjing Drum Tower Hospital of N...
Not yet recruiting
Last update posted :
08/12/2021
Initiation :
09/01/2021
Primary completion :
09/01/2023
Completion :
10/01/2023
CRP
|
Resolor (prucalopride)
Phase 1/2
Gilead Sciences
Completed
Last update posted :
08/12/2021
Initiation :
12/17/2012
Primary completion :
03/01/2019
Completion :
08/13/2020
HER-2
|
HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
Phase 1
Shattuck Labs, Inc.
Recruiting
Last update posted :
08/12/2021
Initiation :
03/26/2019
Primary completion :
02/02/2022
Completion :
04/05/2022
EGFR • ALK • MSI
|
EGFR mutation • MSI-H/dMMR • ALK fusion
|
TAK-252
Phase 4
Germans Trias i Pujol Hospital
Recruiting
Last update posted :
08/12/2021
Initiation :
02/11/2020
Primary completion :
03/01/2022
Completion :
03/01/2022
FGFR3 • CDH1 • CD14 • KRT14 • CDH2 • G0S2 • GAPDH • KRT5 • CDKN1A • KRT20
Phase 2
Matthew Galsky
Active, not recruiting
Last update posted :
08/12/2021
Initiation :
04/17/2018
Primary completion :
03/01/2022
Completion :
03/01/2023
BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • CHEK1 • RAD50 • RAD54L • BRCA • FANCF • ERCC5 • RAD52 • WRN • XRCC2 • FANCD2 • FANCG • NBN • RECQL4 • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • ERCC4 • FANCC
|
Lynparza (olaparib)
Phase N/A
Hopital Foch
Recruiting
Last update posted :
08/11/2021
Initiation :
07/30/2021
Primary completion :
07/01/2023
Completion :
07/01/2025
TMB
Phase 1
University of Florida
Recruiting
Last update posted :
08/11/2021
Initiation :
01/10/2020
Primary completion :
01/01/2022
Completion :
10/01/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Active, not recruiting
Last update posted :
08/10/2021
Initiation :
05/01/2016
Primary completion :
07/06/2020
Completion :
01/30/2026
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • gemcitabine
Phase 1
Emory University
Recruiting
Last update posted :
08/09/2021
Initiation :
07/23/2021
Primary completion :
01/21/2025
Completion :
01/21/2025
PD-L1 • PD-1
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin)
Phase 2
Pfizer
Active, not recruiting
Last update posted :
08/09/2021
Initiation :
05/02/2018
Primary completion :
06/28/2022
Completion :
06/28/2022
PD-L1 • ALK • TMB • ROS1
|
PD-L1 expression • ALK translocation
|
cisplatin • Bavencio (avelumab) • Inlyta (axitinib)
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Recruiting
Last update posted :
08/04/2021
Initiation :
10/26/2020
Primary completion :
11/01/2022
Completion :
11/01/2022
PD-L1 • CD8
|
PD-L1 expression
|
Opdivo (nivolumab) • cisplatin • CG0070
Phase 1
Incyte Corporation
Recruiting
Last update posted :
08/04/2021
Initiation :
02/03/2021
Primary completion :
07/29/2023
Completion :
07/29/2023
CD8
|
retifanlimab (INCMGA0012) • INCB106385
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
08/02/2021
Initiation :
02/26/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
SLC1A5
Phase 1
Corvus Pharmaceuticals, Inc.
Recruiting
Last update posted :
07/27/2021
Initiation :
04/25/2018
Primary completion :
03/01/2022
Completion :
12/01/2023
MSI
|
Keytruda (pembrolizumab) • ciforadenant (CPI-444) • mupadolimab (CPI-006)
Phase 1/2
Dragonfly Therapeutics
Recruiting
Last update posted :
07/26/2021
Initiation :
07/10/2020
Primary completion :
09/01/2022
Completion :
12/01/2024
EGFR • HER-2 • BRAF • ALK • ER • PGR • ROS1
|
EGFR mutation • BRAF mutation • BRAF V600 • HER-2 negative • RET mutation • ER negative • PGR negative
|
Opdivo (nivolumab) • DF6002
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
07/23/2021
Initiation :
12/14/2020
Primary completion :
12/30/2024
Completion :
12/30/2038
HER-2
|
HER-2 positive
|
TT16
Phase 1
Inhibrx, Inc.
Recruiting
Last update posted :
07/22/2021
Initiation :
01/30/2019
Primary completion :
11/01/2022
Completion :
03/01/2023
EGFR • ALK
|
EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab) • INBRX-105
Phase 1b/2
Basilea Pharmaceutica
Recruiting
Last update posted :
07/21/2021
Initiation :
07/25/2019
Primary completion :
07/01/2023
Completion :
10/01/2023
FGFR2
|
FGFR2 mutation • FGFR3 mutation
|
Tecentriq (atezolizumab) • derazantinib (ARQ 087)
Phase N/A
Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting
Last update posted :
07/21/2021
Initiation :
03/30/2017
Primary completion :
12/01/2021
Completion :
12/01/2021
TMB
Phase 1
Inhibrx, Inc.
Recruiting
Last update posted :
07/20/2021
Initiation :
12/10/2019
Primary completion :
12/02/2022
Completion :
03/15/2023
EGFR • PD-L1 • ALK
|
EGFR mutation • ALK rearrangement
|
Keytruda (pembrolizumab) • INBRX-106
Phase 1
GlaxoSmithKline
Recruiting
Last update posted :
07/20/2021
Initiation :
10/15/2020
Primary completion :
06/08/2022
Completion :
12/01/2022
PD-L1
|
bintrafusp alfa (M7824)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
07/20/2021
Initiation :
02/01/2016
Primary completion :
02/01/2022
Completion :
02/01/2022
HER-2 • MUC16
|
HER-2 amplification • HER-2 L755S • HER-2 V777L • HER-2 S310F • HER-2 G778_P780dup • HER-2 A775
|
Kadcyla (ado-trastuzumab emtansine)
Phase 
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Un...
Not yet recruiting
Last update posted :
07/19/2021
Initiation :
09/01/2021
Primary completion :
08/31/2022
Completion :
08/31/2022
GATA3
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
07/16/2021
Initiation :
01/19/2018
Primary completion :
01/31/2022
Completion :
01/31/2022
PD-L1 • CD4
|
PD-L1 expression
|
cisplatin • Tecentriq (atezolizumab) • Halaven (eribulin mesylate)
Phase N/A
Hospices Civils de Lyon
Recruiting
Last update posted :
07/16/2021
Initiation :
12/04/2018
Primary completion :
01/04/2028
Completion :
01/04/2028
MUC16
|
BRAF V600E • EGFR mutation • BRAF V600 • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
|
cisplatin
Phase 1/2
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Not yet recruiting
Last update posted :
07/15/2021
Initiation :
09/01/2021
Primary completion :
11/01/2023
Completion :
03/01/2024
PD-L1 • TMB
|
PD-L1 expression
|
cisplatin • Baize’an (tislelizumab) • APL-1202
Phase 1
Jonsson Comprehensive Cancer Center
Recruiting
Last update posted :
07/14/2021
Initiation :
12/20/2018
Primary completion :
09/01/2022
Completion :
09/01/2023
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • etoposide IV
Phase 2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
07/07/2021
Initiation :
11/01/2021
Primary completion :
12/31/2023
Completion :
12/31/2023
ARID1A • CXCL13
|
ARID1A mutation
|
Opdivo (nivolumab)
Phase 2
Deepak Kilari
Recruiting
Last update posted :
07/05/2021
Initiation :
05/21/2020
Primary completion :
03/01/2022
Completion :
03/01/2023
CD4
|
cisplatin • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet)
Phase 1/2
Incyte Corporation
Recruiting
Last update posted :
07/02/2021
Initiation :
02/27/2015
Primary completion :
12/14/2020
Completion :
09/15/2021
FGFR
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine • docetaxel • Pemazyre (pemigatinib) • retifanlimab (INCMGA0012)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
12/01/2016
Primary completion :
06/30/2022
Completion :
06/30/2022
TSC2 • TSC1
|
TSC1 mutation • TSC2 mutation
|
sapanisertib (TAK-228)
Phase 2
Incyte Corporation
Active, not recruiting
Last update posted :
07/02/2021
Initiation :
01/12/2017
Primary completion :
09/30/2021
Completion :
09/30/2021
FGFR3 • FGFR
|
FGFR3 mutation
|
Pemazyre (pemigatinib)
Phase 2
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Recruiting
Last update posted :
06/28/2021
Initiation :
12/21/2018
Primary completion :
12/31/2023
Completion :
12/31/2023
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • cyclophosphamide oral • DPX-Survivac (maveropepimut-S) • cyclophosphamide intravenous
Phase 1/2
Genocea Biosciences, Inc.
Active, not recruiting
Last update posted :
06/25/2021
Initiation :
08/29/2018
Primary completion :
03/01/2022
Completion :
03/01/2022
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
06/24/2021
Initiation :
02/07/2014
Primary completion :
03/24/2021
Completion :
03/24/2021
GAPDH • MAGEA3
|
fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR • cyclophosphamide intravenous
Phase 3
Eli Lilly and Company
Active, not recruiting
Last update posted :
06/22/2021
Initiation :
07/13/2015
Primary completion :
04/21/2017
Completion :
12/30/2021
PD-L1 • PD-1 • CTLA4
|
docetaxel • Cyramza (ramucirumab)
Phase 2
University of Turin, Italy
Active, not recruiting
Last update posted :
06/21/2021
Initiation :
08/27/2019
Primary completion :
09/01/2021
Completion :
06/01/2024
HRD • BRCA
|
HRD • BRCA mutation
|
Zejula (niraparib)
Phase 1
Rutgers, The State University of New Jersey
Completed
Last update posted :
06/18/2021
Initiation :
08/17/2017
Primary completion :
01/08/2020
Completion :
01/30/2020
EGFR • PD-L1 • ALK
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • troriluzole (BHV-4157)
Phase 1/2
Beijing InnoCare Pharma Tech Co., Ltd.
Recruiting
Last update posted :
06/16/2021
Initiation :
02/01/2021
Primary completion :
10/21/2022
Completion :
02/16/2023
FGFR
|
gunagratinib (ICP-192)
Phase N/A
AstraZeneca
Active, not recruiting
Last update posted :
06/15/2021
Initiation :
01/17/2019
Primary completion :
02/05/2021
Completion :
06/07/2023
PD-L1
|
PD-L1 expression
Phase 1/2
RenJi Hospital
Recruiting
Last update posted :
06/11/2021
Initiation :
06/01/2021
Primary completion :
12/01/2021
Completion :
08/01/2023
PD-L1
|
Baize’an (tislelizumab)
Phase N/A
Duke University
Recruiting
Last update posted :
06/10/2021
Initiation :
03/07/2017
Primary completion :
12/01/2021
Completion :
12/01/2021
PD-L1 • PD-1 • LAG3 • CTLA4 • CD27
|
TILs
Phase 1
Exelixis
Recruiting
Last update posted :
06/07/2021
Initiation :
03/20/2019
Primary completion :
11/01/2023
Completion :
11/01/2024
HER-2 • PD-L1
|
HR positive
|
Tecentriq (atezolizumab) • Bavencio (avelumab) • XL092
Phase 2
BeiGene
Completed
Last update posted :
06/03/2021
Initiation :
07/04/2017
Primary completion :
02/28/2019
Completion :
02/26/2021
PD-L1
|
PD-L1 expression
|
Baize’an (tislelizumab)
Phase N/A
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
06/03/2021
Initiation :
05/01/2009
Primary completion :
05/31/2023
Completion :
05/31/2023
GSTM1
Phase 2
Tianjin Medical University Second Hospital
Recruiting
Last update posted :
06/02/2021
Initiation :
12/27/2020
Primary completion :
02/01/2024
Completion :
07/01/2024
PD-L1 • TMB
|
PD-L1 expression
|
Abraxane (albumin-bound paclitaxel) • Baize’an (tislelizumab)
Phase 1b
Atreca, Inc.
Recruiting
Last update posted :
06/02/2021
Initiation :
02/11/2020
Primary completion :
12/01/2024
Completion :
03/01/2025
BRAF • MSI
|
MSI-H/dMMR • BRAF mutation
|
Keytruda (pembrolizumab) • ATRC-101
Phase 2a
Janssen Research & Development, LLC
Active, not recruiting
Last update posted :
05/27/2021
Initiation :
07/08/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
FGFR
|
FGFR mutation
|
Balversa (erdafitinib)
Phase 1b/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/26/2021
Initiation :
04/14/2021
Primary completion :
06/01/2025
Completion :
06/01/2025
MSI
|
MSI-H/dMMR
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)
Phase 2
RemeGen Co., Ltd.
Not yet recruiting
Last update posted :
05/26/2021
Initiation :
09/01/2021
Primary completion :
01/01/2022
Completion :
10/01/2022
HER-2
|
HER-2 expression
|
Aidixi (disitamab vedotin)
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
05/25/2021
Initiation :
01/01/2018
Primary completion :
06/01/2022
Completion :
12/01/2022
EGFR • HER-2 • BRAF • PD-L1 • KRAS • ALK • ER • TP53 • ABL1 • FLT3 • TMB • NRAS • BRCA1 • BRCA2 • PTEN • FGFR2 • NTRK1 • NTRK3 • ROS1 • BCL2 • IDH1 • NTRK2 • IDH2 • HRAS • NPM1 • STK11 • DNMT3A • PDGFRA • RB1 • JAK2 • ERBB3 • NF1 • AKT1 • POLE • CCND1 • MCL1 • PDGFRB • KDR • PBRM1 • PTCH1 • BCL6 • PD-1 • BAP1 • VEGFA • MAP2K2 • MDM2 • MSH6 • CDK4 • FBXW7 • MSH2 • ATRX • CTNNB1 • FGFR4 • TSC2 • WT1 • ERBB4 • TSC1 • CLDN18 • JAK1 • PD-L2 • RAF1 • MDM4 • POLD1 • CHEK2 • FANCA • CEBPA • JAK3 • RICTOR • AURKA • MSH3 • TGFBR2 • CDK6 • CHEK1 • GATA6 • AKT2 • BRCA • CCND3 • MAP3K1 • MYCL • CCND2 • CSF1R • GNAS • HDAC1 • PARP1 • PRDM1 • ZNF217 • CDKN1A • ERCC4 • GATA3 • PARP2 • SDHA
|
FGFR2 fusion • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Phase 3
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
05/20/2021
Initiation :
09/15/2016
Primary completion :
04/29/2020
Completion :
05/31/2022
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/20/2021
Initiation :
04/01/2003
Primary completion :
12/15/2021
Completion :
12/15/2022
MUC16
|
cisplatin • gemcitabine • 5-fluorouracil • leucovorin calcium • fluorouracil topical
Phase 1
Pfizer
Completed
Last update posted :
05/18/2021
Initiation :
02/10/2016
Primary completion :
11/19/2020
Completion :
11/19/2020
EGFR • PD-L1 • ALK
|
EGFR mutation • ALK mutation • PD-L1-H
|
sasanlimab (PF-06801591)
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/17/2021
Initiation :
06/12/2012
Primary completion :
11/29/2018
ER • AFP
|
Istodax (romidepsin)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Completed
Last update posted :
05/14/2021
Initiation :
01/16/2019
Primary completion :
01/21/2020
Completion :
01/21/2020
PD-L1
|
Keytruda (pembrolizumab) • Abraxane (albumin-bound paclitaxel)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Completed
Last update posted :
05/14/2021
Initiation :
03/01/2012
Primary completion :
06/01/2013
Completion :
06/01/2013
EGFR • HER-2 • PTEN • KIT • IL6 • FLT1
|
ascrinvacumab (GT90001)
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/13/2021
Initiation :
03/22/2017
Primary completion :
03/01/2023
Completion :
03/01/2023
PD-L1
|
cisplatin • Tecentriq (atezolizumab) • gemcitabine
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/13/2021
Initiation :
05/29/2018
Primary completion :
12/31/2021
Completion :
12/31/2021
PD-L1
|
Darzalex IV (daratumumab)
Phase 1
Adaptimmune
Recruiting
Last update posted :
05/13/2021
Initiation :
08/20/2019
Primary completion :
04/30/2022
Completion :
04/30/2037
HLA-A • MAGEA4
|
MAGEA4 expression
|
ADP-A2M4CD8 • afamitresgene autoleucel (ADP-A2M4)
Phase 1/2
NKGen Biotech, Inc.
Withdrawn
Last update posted :
05/12/2021
Initiation :
03/01/2021
Primary completion :
08/01/2022
Completion :
02/01/2023
EGFR • HER-2
|
EGFR positive
|
Herceptin (trastuzumab) • Erbitux (cetuximab) • SNK01
Phase 1/2
Sarcoma Oncology Research Center, LLC
Recruiting
Last update posted :
05/07/2021
Initiation :
08/24/2017
Primary completion :
12/01/2021
Completion :
04/01/2022
PD-L1 • MSI
|
MSI-H/dMMR
|
Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
Phase 1/2
University College, London
Not yet recruiting
Last update posted :
05/07/2021
Initiation :
07/01/2021
Primary completion :
08/31/2024
Completion :
09/30/2028
HLA-A
|
HLA-A*02:01 positive
|
Imfinzi (durvalumab) • S-588210
Phase 2
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
05/07/2021
Initiation :
01/11/2018
Primary completion :
12/30/2021
Completion :
12/30/2022
PD-1
|
Keytruda (pembrolizumab)
Phase 
Hellenic Cooperative Oncology Group
Completed
Last update posted :
05/04/2021
Initiation :
05/01/2000
Primary completion :
03/01/2017
Completion :
06/01/2017
PD-L1
|
PD-L1 expression
Phase 1
Xencor, Inc.
Recruiting
Last update posted :
04/29/2021
Initiation :
07/10/2018
Primary completion :
02/28/2022
Completion :
02/28/2023
HER-2 • ER • PGR • MSI
|
MSI-H/dMMR • HER-2 negative
|
vudalimab (XmAb717)
Phase 2
Shanghai Miracogen Inc.
Recruiting
Last update posted :
04/23/2021
Initiation :
04/20/2021
Primary completion :
06/01/2022
Completion :
09/01/2022
HER-2
|
HER-2 positive
|
MRG002
Phase 1/2
Mamta Parikh
Recruiting
Last update posted :
04/23/2021
Initiation :
04/08/2021
Primary completion :
05/01/2023
Completion :
05/01/2024
PD-L1 • CD4
|
Keytruda (pembrolizumab) • cisplatin • Xpovio (selinexor)
Phase 1a/1b
Tempest Therapeutics
Recruiting
Last update posted :
04/22/2021
Initiation :
05/06/2020
Primary completion :
08/31/2021
Completion :
07/31/2022
PD-L1
|
Keytruda (pembrolizumab) • TPST-1495
Phase 2
CG Oncology, Inc.
Completed
Last update posted :
04/14/2021
Initiation :
06/02/2015
Primary completion :
08/01/2018
Completion :
02/01/2019
PD-L1 • PD-1
|
CG0070
Phase 1b/2
Clovis Oncology, Inc.
Active, not recruiting
Last update posted :
04/13/2021
Initiation :
06/28/2019
Primary completion :
10/01/2023
Completion :
03/01/2024
BRCA1 • BRCA2 • RAD51C • RAD51D
|
BRCA1 mutation • BRCA2 mutation • PALB2 mutation • RAD51D mutation • RAD51C mutation • RAD51 mutation
|
Rubraca (rucaparib) • Trodelvy (sacituzumab govitecan-hziy) • lucitanib (E 3810)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
04/12/2021
Initiation :
05/16/2017
Primary completion :
09/01/2021
Completion :
03/01/2022
PD-L1 • PD-1 • TNFRSF9
|
PD-L1 expression • PD-1 expression
|
Opdivo (nivolumab) • cisplatin • urelumab (BMS-663513)
Phase 1/2
Seagen Inc.
Completed
Last update posted :
04/08/2021
Initiation :
11/30/2015
Primary completion :
12/13/2017
Completion :
12/13/2017
MUC16
|
Tivdak (tisotumab vedotin-tftv)
Phase 2
Tianjin Medical University Second Hospital
Recruiting
Last update posted :
04/06/2021
Initiation :
07/11/2020
Primary completion :
02/01/2024
Completion :
07/01/2024
PD-L1 • TMB
|
PD-L1 expression
|
Abraxane (albumin-bound paclitaxel) • Baize’an (tislelizumab)
Phase 2
Rahul Aggarwal
Recruiting
Last update posted :
04/06/2021
Initiation :
01/17/2019
Primary completion :
12/31/2023
Completion :
12/31/2023
ATM • ARID1A • UGT1A1
|
ATM mutation • ATM expression • UGT1A1*1*1
|
Lynparza (olaparib) • ceralasertib (AZD6738)
Phase 1
Eli Lilly and Company
Active, not recruiting
Last update posted :
04/06/2021
Initiation :
07/29/2015
Primary completion :
08/31/2018
Completion :
10/30/2021
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Cyramza (ramucirumab)
Phase 1
University Health Network, Toronto
Recruiting
Last update posted :
04/01/2021
Initiation :
09/01/2016
Primary completion :
09/01/2021
Completion :
09/01/2021
CTAG1B • HLA-A
|
CTAG1B expression
|
fludarabine IV • cyclophosphamide intravenous • mipetresgene autoleucel (TBI-1301)
Phase 1
Lindis Biotech GmbH
Recruiting
Last update posted :
03/29/2021
Initiation :
07/07/2020
Primary completion :
12/30/2021
Completion :
12/30/2023
EPCAM
|
EPCAM expression
|
Removab (catumaxomab)
Phase 3
UNICANCER
Recruiting
Last update posted :
03/29/2021
Initiation :
01/17/2019
Primary completion :
04/01/2022
Completion :
02/01/2028
PD-L1
|
PD-L1 expression
|
Tecentriq (atezolizumab) • Tice BCG (live attenuated bacillus Calmette-Guerin)
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
03/29/2021
Initiation :
03/07/2017
Primary completion :
03/31/2021
Completion :
03/31/2022
IL17A
|
cisplatin • Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase N/A
University Teaching Hospital Hall in Tirol
Recruiting
Last update posted :
03/23/2021
Initiation :
03/14/2021
Primary completion :
08/01/2022
Completion :
08/01/2025
PTPRC
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/22/2021
Initiation :
06/24/2005
Primary completion :
08/15/2010
EGFR • BIRC5 • CASP3
|
EGFR mutation
Phase 1
The University of Texas Health Science Center a...
Completed
Last update posted :
03/19/2021
Initiation :
06/01/2016
Primary completion :
12/01/2019
Completion :
03/02/2021
CD8 • IFNG • CD4
|
sirolimus
Phase 2
Jørgen Bjerggaard Jensen
Recruiting
Last update posted :
03/17/2021
Initiation :
03/24/2020
Primary completion :
08/01/2022
Completion :
11/01/2024
PD-L1
|
PD-L1 expression
|
cisplatin • Tecentriq (atezolizumab)
Phase 1
Checkpoint Therapeutics, Inc.
Recruiting
Last update posted :
03/16/2021
Initiation :
09/20/2017
Primary completion :
07/01/2021
Completion :
12/01/2022
MSI
|
MSI-H/dMMR
|
cosibelimab (CK-301)
Phase 2
Barbara Ann Karmanos Cancer Institute
Active, not recruiting
Last update posted :
03/12/2021
Initiation :
04/24/2018
Primary completion :
12/01/2021
Completion :
12/01/2021
PD-L1 • PD-1
|
PD-L1 expression
|
Opdivo (nivolumab)
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
06/14/2016
Primary completion :
11/30/2017
Completion :
12/31/2021
TP53 • MSI • PD-1
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
Phase 3
UNICANCER
Completed
Last update posted :
03/09/2021
Initiation :
06/01/2010
Primary completion :
09/01/2016
Completion :
09/01/2017
KRAS
|
cisplatin • Vectibix (panitumumab) • doxorubicin hydrochloride • vinblastine
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51 • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • RAD51D mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • BARD1 mutation • NBN mutation
|
Zejula (niraparib) • Jemperli (dostarlimab)
Phase N/A
AstraZeneca
Completed
Last update posted :
03/01/2021
Initiation :
10/25/2019
Primary completion :
03/23/2020
Completion :
03/23/2020
PD-L1 • TMB
|
PD-L1-H
Phase 2
Merck Sharp & Dohme Corp.
Recruiting
Last update posted :
03/01/2021
Initiation :
02/10/2016
Primary completion :
06/15/2022
Completion :
07/30/2023
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab)
Phase 1
BioNTech US Inc.
Completed
Last update posted :
02/25/2021
Initiation :
10/01/2016
Primary completion :
02/01/2019
Completion :
05/01/2020
BRAF
|
Opdivo (nivolumab) • Hiltonol (poly-ICLC) • Neo Vax (NEO-PV-01)
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Recruiting
Last update posted :
02/25/2021
Initiation :
09/25/2019
Primary completion :
02/01/2023
Completion :
02/01/2023
PD-L1
|
cisplatin • Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet)
Phase 2
UNC Lineberger Comprehensive Cancer Center
Recruiting
Last update posted :
02/22/2021
Initiation :
09/23/2020
Primary completion :
10/01/2022
Completion :
11/01/2022
CD8
|
Keytruda (pembrolizumab) • cisplatin • entinostat (SNDX-275)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
02/18/2021
Initiation :
02/23/2021
Primary completion :
05/19/2024
Completion :
05/19/2025
ALB
|
HER-2 positive • HR positive
|
Hyleukin-7 (efineptakin alfa)
Phase 1/2
Incyte Corporation
Completed
Last update posted :
02/16/2021
Initiation :
07/17/2014
Primary completion :
11/26/2018
Completion :
11/06/2020
HER-2 • BRAF • ALK • ER • PGR • MSI
|
BRAF V600E • EGFR mutation • MSI-H/dMMR • BRAF V600 • HER-2 negative • ALK positive • ALK fusion
|
Keytruda (pembrolizumab) • epacadostat (INCB024360)
Phase 1/2
Monika Joshi, MD
Active, not recruiting
Last update posted :
02/08/2021
Initiation :
11/01/2016
Primary completion :
03/01/2021
Completion :
03/01/2022
PD-L1
|
PD-L1 expression
|
cisplatin • Imfinzi (durvalumab)
Phase 1
Kyowa Kirin Pharmaceutical Development, Inc.
Recruiting
Last update posted :
02/08/2021
Initiation :
09/26/2019
Primary completion :
12/31/2021
Completion :
02/25/2022
PD-L1
|
Bavencio (avelumab) • KHK2455
Phase N/A
University of Pittsburgh
Active, not recruiting
Last update posted :
02/04/2021
Initiation :
06/01/2017
Primary completion :
12/31/2020
Completion :
12/31/2024
SOD2
Phase 1b
Pieris Pharmaceuticals, Inc.
Active, not recruiting
Last update posted :
02/02/2021
Initiation :
08/21/2018
Primary completion :
05/01/2021
Completion :
07/01/2021
HER-2
|
Tecentriq (atezolizumab) • cinrebafusp alfa (PRS-343)
Phase 1
Pieris Pharmaceuticals, Inc.
Recruiting
Last update posted :
02/01/2021
Initiation :
09/28/2017
Primary completion :
05/01/2021
Completion :
09/01/2021
HER-2 • TNFRSF9
|
cinrebafusp alfa (PRS-343)
Phase 1
Nanobiotix
Recruiting
Last update posted :
01/29/2021
Initiation :
01/16/2019
Primary completion :
03/30/2023
Completion :
03/30/2023
PD-1
|
Hensify (crystalline hafnium oxide)
Phase 1b/2a
Ocellaris Pharma, Inc.
Recruiting
Last update posted :
01/27/2021
Initiation :
10/06/2020
Primary completion :
11/01/2022
Completion :
11/01/2022
HER-2 • ALK • ER • PGR • ROS1
|
HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion
|
OC-001
Phase 
University Hospital, Bordeaux
Completed
Last update posted :
01/27/2021
Initiation :
03/16/2020
Primary completion :
05/14/2020
Completion :
05/14/2020
PD-L1
|
PD-L1 expression
Phase 2
Merck Sharp & Dohme Corp.
Active, not recruiting
Last update posted :
01/26/2021
Initiation :
02/24/2015
Primary completion :
06/19/2018
Completion :
12/28/2021
PD-L1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • cisplatin
Phase 3
Immunomedics, Inc.
Recruiting
Last update posted :
01/25/2021
Initiation :
11/16/2020
Primary completion :
04/01/2023
Completion :
06/01/2024
ALB
|
cisplatin • paclitaxel • docetaxel • Trodelvy (sacituzumab govitecan-hziy) • Javlor (vinflunine)
Phase 2
Institute of Biophysics and Cell Engineering of...
Completed
Last update posted :
01/22/2021
Initiation :
07/01/2019
Primary completion :
12/31/2020
Completion :
12/31/2020
WT1
|
MUC1 expression
Phase 2
Australian and New Zealand Urogenital and Prost...
Recruiting
Last update posted :
01/20/2021
Initiation :
08/01/2016
Primary completion :
09/01/2023
Completion :
01/01/2024
ALB
|
Keytruda (pembrolizumab) • cisplatin
Phase 2
NYU Langone Health
Active, not recruiting
Last update posted :
01/07/2021
Initiation :
08/11/2016
Primary completion :
12/01/2025
Completion :
12/01/2025
ALB
|
Keytruda (pembrolizumab) • gemcitabine
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/06/2021
Initiation :
05/15/2018
Primary completion :
07/31/2022
Completion :
07/31/2022
mTOR
|
Sutent (sunitinib) • Cabometyx (cabozantinib tablet)
Phase 2
Matthew Galsky
Active, not recruiting
Last update posted :
01/06/2021
Initiation :
11/11/2015
Primary completion :
07/01/2019
Completion :
01/01/2021
PD-L1
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab)
Phase N/A
Mansoura University
Recruiting
Last update posted :
12/21/2020
Initiation :
11/28/2020
Primary completion :
11/28/2022
Completion :
11/28/2023
BCL2
Phase 1
Adaptimmune
Completed
Last update posted :
12/18/2020
Initiation :
10/01/2016
Primary completion :
12/18/2019
Completion :
06/04/2020
HLA-A
|
ADP-A2M10
Phase 2b
UroGen Pharma Ltd.
Completed
Last update posted :
12/11/2020
Initiation :
10/15/2018
Primary completion :
01/03/2020
Completion :
10/21/2020
ALB
|
VesiGel (mitomycin intravesicular)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
12/07/2020
Initiation :
04/11/2019
Primary completion :
01/31/2021
Completion :
01/31/2021
MTAP • IL17A
|
cisplatin • Bavencio (avelumab) • pemetrexed
Phase 1
Incyte Corporation
Active, not recruiting
Last update posted :
12/04/2020
Initiation :
01/25/2016
Primary completion :
11/07/2019
Completion :
12/24/2021
EGFR • ALK • FOXP3
|
EGFR mutation • ALK translocation
|
Keytruda (pembrolizumab) • parsaclisib (INCB50465) • itacitinib (INCB039110)
Phase 1b
Cantargia AB
Recruiting
Last update posted :
11/18/2020
Initiation :
09/24/2020
Primary completion :
01/01/2022
Completion :
01/01/2022
IL6 • CRP
|
Keytruda (pembrolizumab) • nidanilimab (CAN04)
Phase 2
Boehringer Ingelheim
Completed
Last update posted :
11/18/2020
Initiation :
06/09/2016
Primary completion :
09/24/2018
Completion :
09/02/2019
EGFR • HER-2 • ERBB3
|
HER-2 amplification • HER-2 mutation • EGFR amplification • ERBB3 mutation
|
Gilotrif (afatinib)
Phase 1/2
Aprea Therapeutics
Recruiting
Last update posted :
11/16/2020
Initiation :
06/25/2020
Primary completion :
12/01/2021
Completion :
06/01/2022
TP53
|
TP53 mutation
|
Keytruda (pembrolizumab) • cisplatin • eprenetapopt (APR-246)
Phase 2
Jun Guo
Not yet recruiting
Last update posted :
11/13/2020
Initiation :
11/30/2020
Primary completion :
01/30/2022
Completion :
01/30/2023
PD-L1
|
cisplatin • Abraxane (albumin-bound paclitaxel) • Tuoyi (toripalimab)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
11/06/2020
Initiation :
03/27/2017
Primary completion :
10/23/2019
Completion :
10/23/2019
CD4
|
Xalkori (crizotinib) • erlotinib • paclitaxel • Sutent (sunitinib) • docetaxel • bortezomib • Jakafi oral (ruxolitinib) • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • carmustine • Zanosar (streptozocin) • Vumon (teniposide) • hydroxyurea
Phase 2
Centre Hospitalier Universitaire de Nīmes
Recruiting
Last update posted :
11/05/2020
Initiation :
06/01/2020
Primary completion :
01/01/2024
Completion :
06/01/2024
CRP
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab)
Phase 2
Hellenic GenitoUrinary Cancer Group
Recruiting
Last update posted :
11/04/2020
Initiation :
11/15/2018
Primary completion :
08/31/2021
Completion :
12/31/2021
PD-L1
|
PD-L1 expression • VEGFA expression
|
Imfinzi (durvalumab)
Phase 2
Hellenic GenitoUrinary Cancer Group
Recruiting
Last update posted :
11/04/2020
Initiation :
05/28/2019
Primary completion :
12/01/2021
Completion :
12/01/2021
PD-L1
|
Opdivo (nivolumab)
Phase 1
Archivel Farma S.L.
Active, not recruiting
Last update posted :
11/04/2020
Initiation :
06/16/2017
Primary completion :
03/24/2020
Completion :
03/01/2023
IFNG
|
RUTI (Mycobacterium tuberculosis cell wall nanofragmanets suspension)
Phase N/A
University of Miami
Completed
Last update posted :
11/03/2020
Initiation :
07/01/2011
Primary completion :
12/01/2018
Completion :
12/01/2018
ALB
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
10/29/2020
Initiation :
12/01/2008
Primary completion :
12/01/2021
Completion :
12/01/2021
EIF4EBP1
|
cisplatin • everolimus • sirolimus
Phase 1
Fundacion Oncosur
Recruiting
Last update posted :
10/28/2020
Initiation :
02/03/2020
Primary completion :
02/01/2023
Completion :
02/01/2023
PD-L1
|
Tecentriq (atezolizumab)
Phase 1
M.D. Anderson Cancer Center
Recruiting
Last update posted :
10/23/2020
Initiation :
07/28/2020
Primary completion :
12/31/2021
Completion :
12/31/2021
FGFR3
|
FGFR3 expression
|
Truseltiq (infigratinib)
Phase 1/2
GB006, Inc., a wholly owned subsidiary of Gossa...
Recruiting
Last update posted :
10/16/2020
Initiation :
08/13/2019
Primary completion :
03/01/2023
Completion :
03/01/2023
PD-L1
|
Keytruda (pembrolizumab) • gemcitabine • Abraxane (albumin-bound paclitaxel) • GB1275
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
10/12/2020
Initiation :
10/01/2020
Primary completion :
09/30/2022
Completion :
09/30/2023
PD-L1
|
Baize’an (tislelizumab) • Epidaza (chidamide)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
10/06/2020
Initiation :
10/02/2020
Primary completion :
05/01/2022
Completion :
05/01/2023
FGFR3
|
FGFR3 mutation
|
Pemazyre (pemigatinib)
Phase 3
Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting
Last update posted :
09/29/2020
Initiation :
11/30/2020
Primary completion :
11/30/2023
Completion :
11/30/2025
PD-L1
|
PD-L1 expression
|
cisplatin • carboplatin • gemcitabine • Tuoyi (toripalimab)
Phase 3
Sahlgrenska University Hospital, Sweden
Recruiting
Last update posted :
09/15/2020
Initiation :
09/02/2020
Primary completion :
12/31/2021
Completion :
12/31/2022
CRP
Phase 3
Incyte Corporation
Completed
Last update posted :
09/14/2020
Initiation :
12/04/2017
Primary completion :
08/09/2018
Completion :
08/04/2020
PD-L1
|
Keytruda (pembrolizumab) • cisplatin • epacadostat (INCB024360)
Phase N/A
Gritstone Oncology, Inc.
Completed
Last update posted :
09/11/2020
Initiation :
07/25/2018
Primary completion :
01/17/2020
Completion :
05/26/2020
EGFR
Phase 3
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
09/10/2020
Initiation :
02/11/2016
Primary completion :
11/30/2020
Completion :
11/27/2026
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab)
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
09/04/2020
Initiation :
03/01/2012
Primary completion :
09/02/2020
Completion :
09/02/2020
PTEN
|
PIK3CA mutation
|
cisplatin • buparlisib (BKM120)
Phase 1
Advaxis, Inc.
Active, not recruiting
Last update posted :
08/11/2020
Initiation :
06/07/2018
Primary completion :
01/31/2022
Completion :
01/31/2022
EGFR
|
PD-L1 expression • MSI-H/dMMR
|
Keytruda (pembrolizumab) • ADXS-NEO
Phase 2
University of Utah
Recruiting
Last update posted :
08/04/2020
Initiation :
09/18/2018
Primary completion :
09/01/2023
Completion :
09/01/2023
ALB
|
Keytruda (pembrolizumab) • cisplatin • Cabometyx (cabozantinib tablet)
Phase 1
Jonsson Comprehensive Cancer Center
Completed
Last update posted :
07/27/2020
Initiation :
08/22/2013
Primary completion :
01/06/2017
Completion :
01/06/2017
PSCA
Phase 1b
AstraZeneca
Active, not recruiting
Last update posted :
07/23/2020
Initiation :
10/03/2016
Primary completion :
03/18/2020
Completion :
02/14/2022
CDKN2A • RB1 • HRD • CCNE1 • MYCN • MYCL
|
CDKN2A deletion • FGFR3 mutation • CDKN2A mutation • CCNE1 amplification • RB1 deletion • FGFR fusion • MYCL amplification
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • ABSK-091 • vistusertib (AZD2014) • danvatirsen (AZD9150)
Phase N/A
Assiut University
Not yet recruiting
Last update posted :
07/08/2020
Initiation :
12/01/2020
Primary completion :
10/01/2021
Completion :
12/31/2021
ATG7
Phase 2
Bristol-Myers Squibb
Active, not recruiting
Last update posted :
07/08/2020
Initiation :
03/04/2015
Primary completion :
04/15/2016
Completion :
08/29/2021
PD-L1
|
PD-L1 expression
|
Opdivo (nivolumab)
Phase 2
Viventia Bio
Completed
Last update posted :
05/12/2020
Initiation :
03/01/2007
Primary completion :
10/01/2009
Completion :
10/01/2009
EPCAM
|
Vicineum (oportuzumab monatox)
Phase 1
Apexigen, Inc.
Completed
Last update posted :
04/28/2020
Initiation :
05/01/2015
Primary completion :
06/13/2018
Completion :
06/19/2018
MSI
|
MSI-H/dMMR
|
sotigalimab (APX005M)
Phase 1/2
Noah Hahn, M.D.
Recruiting
Last update posted :
04/17/2020
Initiation :
11/21/2017
Primary completion :
09/01/2022
Completion :
03/01/2023
PD-L1
|
Imfinzi (durvalumab)
Phase 
Ho Kyung Seo
Not yet recruiting
Last update posted :
04/09/2020
Initiation :
05/01/2020
Primary completion :
03/31/2022
Completion :
03/31/2025
PD-L1 • FGFR
|
PD-L1 expression • FGFR mutation
Phase 1
NCIC Clinical Trials Group
Completed
Last update posted :
04/08/2020
Initiation :
03/06/2003
Primary completion :
03/09/2006
Completion :
12/21/2009
CLU
|
docetaxel • custirsen (OGX-011)
Phase 2
Dana-Farber Cancer Institute
Recruiting
Last update posted :
04/08/2020
Initiation :
12/28/2017
Primary completion :
05/31/2021
Completion :
05/31/2025
ALB
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
Lawrence Fong
Recruiting
Last update posted :
03/30/2020
Initiation :
06/28/2016
Primary completion :
12/31/2020
Completion :
12/31/2021
PD-1
|
PD-L1 expression
|
cisplatin • Tecentriq (atezolizumab)
Phase 1b
Taris Biomedical LLC
Completed
Last update posted :
03/10/2020
Initiation :
01/01/2016
Primary completion :
01/01/2018
Completion :
03/01/2020
CD31
|
gemcitabine • GemRIS (gemcitabine-releasing intravesical system)
Phase 
Assiut University
Not yet recruiting
Last update posted :
03/05/2020
Initiation :
05/01/2020
Primary completion :
05/01/2021
Completion :
05/01/2022
CD31
Phase 1
Astellas Pharma Inc
Completed
Last update posted :
03/04/2020
Initiation :
04/24/2017
Primary completion :
02/25/2019
Completion :
02/25/2019
NECTIN4
|
NECTIN4 expression
|
Padcev (enfortumab vedotin)
Phase 1b/2
NanoCarrier Co., Ltd.
Completed
Last update posted :
02/28/2020
Initiation :
05/01/2014
Primary completion :
05/06/2019
Completion :
05/06/2019
EGFR • ALK
|
EGFR mutation • ALK fusion
|
cisplatin • gemcitabine • Nanoplatin (demplatin pegraglumer)
Phase 1/2
Beijing Cancer Hospital
Recruiting
Last update posted :
02/13/2020
Initiation :
02/15/2020
Primary completion :
01/30/2021
Completion :
12/31/2021
HER-2 • PD-L1
|
cisplatin • Tuoyi (toripalimab) • Aidixi (disitamab vedotin)
Phase 1
Herlev Hospital
Recruiting
Last update posted :
02/12/2020
Initiation :
12/17/2018
Primary completion :
12/01/2020
Completion :
06/01/2021
PD-L1 • PD-1
|
IO112
Phase 1
Zhujiang Hospital
Completed
Last update posted :
01/22/2020
Initiation :
04/14/2017
Primary completion :
06/04/2019
Completion :
06/04/2019
CTAG1B
|
TAEST16001
Phase 1b
Taris Biomedical LLC
Completed
Last update posted :
01/13/2020
Initiation :
05/31/2016
Primary completion :
05/02/2019
Completion :
05/02/2019
PD-L1 • CD8 • CD31 • CD4
|
cisplatin • gemcitabine • GemRIS (gemcitabine-releasing intravesical system)
Phase N/A
Astellas Pharma Global Development, Inc.
Approved for marketing
Last update posted :
01/13/2020
PD-L1
|
cisplatin • Padcev (enfortumab vedotin)
Phase 1
MacroGenics
Completed
Last update posted :
01/09/2020
Initiation :
07/01/2011
Primary completion :
04/18/2019
Completion :
04/18/2019
CD276
|
CD276 overexpression
|
enoblituzumab (MGA271)
Phase N/A
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/07/2020
Initiation :
09/01/1994
Primary completion :
09/30/2020
Completion :
09/30/2020
MSH2
Phase 1
M.D. Anderson Cancer Center
Active, not recruiting
Last update posted :
01/07/2020
Initiation :
08/16/2017
Primary completion :
08/31/2020
Completion :
08/31/2020
IL6
Phase 2
Dana-Farber Cancer Institute
Withdrawn
Last update posted :
12/17/2019
Initiation :
11/27/2019
Primary completion :
11/27/2019
Completion :
11/27/2019
ALB
|
FGFR1 expression
|
rogaratinib (BAY1163877)
Phase 1
Celgene
Completed
Last update posted :
11/11/2019
Initiation :
11/29/2011
Primary completion :
11/17/2015
Completion :
11/17/2015
DNMT1
|
carboplatin • Abraxane (albumin-bound paclitaxel) • Onureg (azacitidine oral)
Phase N/A
Mansoura University
Completed
Last update posted :
11/04/2019
Initiation :
08/01/2018
Primary completion :
05/01/2019
Completion :
05/01/2019
TERT • MIR155
Phase 1
University of Maryland, Baltimore
Completed
Last update posted :
11/04/2019
Initiation :
04/01/2000
Primary completion :
12/01/2003
Completion :
12/01/2003
ALB
Phase 1
Novartis Pharmaceuticals
Completed
Last update posted :
10/04/2019
Initiation :
12/11/2009
Primary completion :
10/08/2018
Completion :
10/08/2018
FGFR2 • FGFR3
|
FGFR1 amplification • FGFR2 mutation • FGFR2 amplification • FGFR3 mutation • FGFR3 amplification
|
Truseltiq (infigratinib)
Phase 2
Samsung Medical Center
Recruiting
Last update posted :
09/25/2019
Initiation :
11/12/2015
Primary completion :
12/01/2019
Completion :
03/01/2020
HRAS • STK11
|
STK11 mutation • HRAS mutation
|
Zarnestra (tipifarnib)
Phase 2
Eli Lilly and Company
Completed
Last update posted :
09/09/2019
Initiation :
04/01/2011
Primary completion :
02/01/2015
Completion :
03/01/2015
KDR • FLT1 • VEGFB
|
docetaxel • Cyramza (ramucirumab) • icrucumab (IMC-18F1)
Phase 2
Hoffmann-La Roche
Completed
Last update posted :
08/28/2019
Initiation :
12/23/2016
Primary completion :
04/10/2018
Completion :
04/10/2018
HER-2
|
HER-2 positive
|
Kadcyla (ado-trastuzumab emtansine)
Phase 2
RemeGen
Completed
Last update posted :
08/21/2019
Initiation :
12/28/2017
Primary completion :
10/29/2018
Completion :
10/29/2018
HER-2
|
HER-2 positive
|
Aidixi (disitamab vedotin)
Phase 2/3
Peking University
Recruiting
Last update posted :
06/20/2019
Initiation :
06/19/2019
Primary completion :
06/20/2022
Completion :
06/20/2023
PD-L1
|
PD-L1 expression
|
cisplatin • carboplatin • 5-fluorouracil • etoposide IV • Tuoyi (toripalimab)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Active, not recruiting
Last update posted :
06/10/2019
Initiation :
10/17/2017
Primary completion :
10/01/2019
Completion :
10/01/2019
PD-L1
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • cisplatin
Phase 1
Mayo Clinic
Completed
Last update posted :
06/06/2019
Initiation :
01/01/2016
Primary completion :
09/05/2017
Completion :
04/24/2018
HER-2 • PIK3CA • STK11 • AKT1 • TSC2 • RHEB
|
HER-2 amplification
|
sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
Phase 1
University Hospital, Ghent
Completed
Last update posted :
05/30/2019
Initiation :
11/14/2016
Primary completion :
04/02/2018
Completion :
02/18/2019
ALB
|
Keytruda (pembrolizumab)
Phase 1
Imperial College London
Recruiting
Last update posted :
05/14/2019
Initiation :
04/10/2019
Primary completion :
08/01/2021
Completion :
02/01/2022
ALB
|
MRx518
Phase 2b
Anchiano Therapeutics Israel Ltd.
Completed
Last update posted :
04/30/2019
Initiation :
01/01/2008
Primary completion :
01/01/2013
Completion :
01/01/2013
H19
|
inodiftagene vixteplasmid (BC 819)
Phase 
RenJi Hospital
Recruiting
Last update posted :
03/27/2019
Initiation :
01/01/2018
Primary completion :
12/31/2019
Completion :
12/31/2019
NPPB
Phase 2
Consorzio Oncotech
Recruiting
Last update posted :
03/26/2019
Initiation :
02/06/2019
Primary completion :
01/01/2021
Completion :
01/01/2021
PD-L1
|
PD-L1 expression
|
cisplatin • Bavencio (avelumab)
Phase 1
Peking University
Withdrawn
Last update posted :
03/06/2019
Initiation :
09/01/2016
Primary completion :
09/01/2019
Completion :
09/01/2019
PD-1 • IL6 • IFNG • IL2
|
cyclophosphamide intravenous
Phase 2
Jiangsu HengRui Medicine Co., Ltd.
Recruiting
Last update posted :
02/04/2019
Initiation :
01/23/2019
Primary completion :
06/01/2020
Completion :
06/01/2021
IL2
|
AiRuiKa (camrelizumab) • famitinib (SHR 1020)
Phase N/A
University of Texas Southwestern Medical Center
Completed
Last update posted :
01/10/2019
Initiation :
06/13/2017
Primary completion :
03/07/2018
Completion :
03/07/2018
STING
Phase 
Medical University of Warsaw
Not yet recruiting
Last update posted :
01/08/2019
Initiation :
01/01/2019
Primary completion :
08/01/2019
Completion :
10/01/2019
MCM5